GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Goodwill-to-Asset

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Goodwill-to-Asset : 0.00 (As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. GlaxoSmithKline Consumer Nigeria's Goodwill for the quarter that ended in Jun. 2023 was ₦0 Mil. GlaxoSmithKline Consumer Nigeria's Total Assets for the quarter that ended in Jun. 2023 was ₦30,268 Mil. Therefore, GlaxoSmithKline Consumer Nigeria's Goodwill to Asset Ratio for the quarter that ended in Jun. 2023 was 0.00.


GlaxoSmithKline Consumer Nigeria Goodwill-to-Asset Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Goodwill-to-Asset Chart

GlaxoSmithKline Consumer Nigeria Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlaxoSmithKline Consumer Nigeria Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlaxoSmithKline Consumer Nigeria's Goodwill-to-Asset

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Consumer Nigeria's Goodwill-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's Goodwill-to-Asset falls into.



GlaxoSmithKline Consumer Nigeria Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

GlaxoSmithKline Consumer Nigeria's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Goodwill to Asset (A: Dec. 2022 )=Goodwill/Total Assets
=0/29386.204
=0.00

GlaxoSmithKline Consumer Nigeria's Goodwill to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Goodwill to Asset (Q: Jun. 2023 )=Goodwill/Total Assets
=0/30268.016
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Consumer Nigeria  (NSA:GLAXOSMITH) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


GlaxoSmithKline Consumer Nigeria Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines